Literature DB >> 16116134

Long-term clinical outcome of primary progressive MS: predictive value of clinical and MRI data.

J Sastre-Garriga1, G T Ingle, M Rovaris, N Téllez, B Jasperse, D R Altmann, B Benedetti, V L Stevenson, M Cercignani, S M Leary, F Barkhof, B Brochet, V Dousset, M Filippi, X Montalban, N F Kalkers, C H Polman, A Rovira, D H Miller, A J Thompson.   

Abstract

The authors sought to identify clinical and MRI predictors of outcome in primary progressive multiple sclerosis (PPMS). Clinical and MRI assessments were performed at baseline and 2 and 5 years (clinical only). At baseline, disease duration, expanded disability status scale (EDSS) and brain volume predicted outcome. Adding short-term change variables, baseline EDSS, changes in T2* lesion load and cord area, and number of new lesions were predictive. Clinical and MRI variables predict long-term outcome in PPMS.

Entities:  

Mesh:

Year:  2005        PMID: 16116134     DOI: 10.1212/01.wnl.0000173061.12776.1f

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  11 in total

Review 1.  Spinal cord MRI in multiple sclerosis--diagnostic, prognostic and clinical value.

Authors:  Hugh Kearney; David H Miller; Olga Ciccarelli
Journal:  Nat Rev Neurol       Date:  2015-05-26       Impact factor: 42.937

2.  Cervical Cord Atrophy and Long-Term Disease Progression in Patients with Primary-Progressive Multiple Sclerosis.

Authors:  F X Aymerich; C Auger; J Alonso; M Alberich; J Sastre-Garriga; M Tintoré; X Montalban; A Rovira
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-28       Impact factor: 3.825

3.  Adding brain volume measures into response criteria in multiple sclerosis: the Río-4 score.

Authors:  Francisco Carlos Pérez-Miralles; Jordi Río; Deborah Pareto; Àngela Vidal-Jordana; Cristina Auger; Georgina Arrambide; Joaquín Castilló; Mar Tintoré; Àlex Rovira; Xavier Montalban; Jaume Sastre-Garriga
Journal:  Neuroradiology       Date:  2020-11-25       Impact factor: 2.804

4.  Reactive astrocytes form scar-like perivascular barriers to leukocytes during adaptive immune inflammation of the CNS.

Authors:  Rhonda R Voskuhl; R Scott Peterson; Bingbing Song; Yan Ao; Laurie Beth J Morales; Seema Tiwari-Woodruff; Michael V Sofroniew
Journal:  J Neurosci       Date:  2009-09-16       Impact factor: 6.167

5.  T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis.

Authors:  B Bodini; M Battaglini; N De Stefano; Z Khaleeli; F Barkhof; D Chard; M Filippi; X Montalban; C Polman; M Rovaris; A Rovira; R Samson; D Miller; A Thompson; O Ciccarelli
Journal:  J Neurol Neurosurg Psychiatry       Date:  2010-07-13       Impact factor: 10.154

Review 6.  A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives.

Authors:  Emanuele D'Amico; Francesco Patti; Aurora Zanghì; Mario Zappia
Journal:  Int J Mol Sci       Date:  2016-10-17       Impact factor: 5.923

7.  Alemtuzumab CARE-MS II 5-year follow-up: Efficacy and safety findings.

Authors:  Alasdair J Coles; Jeffrey A Cohen; Edward J Fox; Gavin Giovannoni; Hans-Peter Hartung; Eva Havrdova; Sven Schippling; Krzysztof W Selmaj; Anthony Traboulsee; D Alastair S Compston; David H Margolin; Karthinathan Thangavelu; Madalina C Chirieac; Darlene Jody; Panos Xenopoulos; Richard J Hogan; Michael A Panzara; Douglas L Arnold
Journal:  Neurology       Date:  2017-08-23       Impact factor: 9.910

8.  Brain Metabolite Changes in Patients with Relapsing-Remitting and Secondary Progressive Multiple Sclerosis: A Two-Year Follow-Up Study.

Authors:  Dorothea Obert; Gunther Helms; Muriel B Sättler; Klaus Jung; Benedikt Kretzschmar; Mathias Bähr; Peter Dechent; Ricarda Diem; Katharina Hein
Journal:  PLoS One       Date:  2016-09-16       Impact factor: 3.240

9.  Brain and cord myelin water imaging: a progressive multiple sclerosis biomarker.

Authors:  Shannon Kolind; Arshia Seddigh; Anna Combes; Bretta Russell-Schulz; Roger Tam; Vignan Yogendrakumar; Sean Deoni; Naomi A Sibtain; Anthony Traboulsee; Steven C R Williams; Gareth J Barker; Peter A Brex
Journal:  Neuroimage Clin       Date:  2015-10-03       Impact factor: 4.881

10.  Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis.

Authors:  Colm Elliott; Shibeshih Belachew; Jerry S Wolinsky; Stephen L Hauser; Ludwig Kappos; Frederik Barkhof; Corrado Bernasconi; Julian Fecker; Fabian Model; Wei Wei; Douglas L Arnold
Journal:  Brain       Date:  2019-09-01       Impact factor: 13.501

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.